HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth

Abstract A major challenge in developing an effective vaccine against HIV-1 is the genetic diversity of its viral envelope. Because of the broad range of sequences exhibited by HIV-1 strains, protective antibodies must be able to bind and neutralize a widely mutated viral envelope protein. No vaccin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chelsea N. Fries, Jui-Lin Chen, Maria L. Dennis, Nicole L. Votaw, Joshua Eudailey, Brian E. Watts, Kelly M. Hainline, Derek W. Cain, Richard Barfield, Cliburn Chan, M. Anthony Moody, Barton F. Haynes, Kevin O. Saunders, Sallie R. Permar, Genevieve G. Fouda, Joel H. Collier
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9b1d282b3398438e8effddf57c228cf2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9b1d282b3398438e8effddf57c228cf2
record_format	dspace
spelling	oai:doaj.org-article:9b1d282b3398438e8effddf57c228cf22021-12-02T18:30:45ZHIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth10.1038/s41598-021-93702-x2045-2322https://doaj.org/article/9b1d282b3398438e8effddf57c228cf22021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93702-xhttps://doaj.org/toc/2045-2322Abstract A major challenge in developing an effective vaccine against HIV-1 is the genetic diversity of its viral envelope. Because of the broad range of sequences exhibited by HIV-1 strains, protective antibodies must be able to bind and neutralize a widely mutated viral envelope protein. No vaccine has yet been designed which induces broadly neutralizing or protective immune responses against HIV in humans. Nanomaterial-based vaccines have shown the ability to generate antibody and cellular immune responses of increased breadth and neutralization potency. Thus, we have developed supramolecular nanofiber-based immunogens bearing the HIV gp120 envelope glycoprotein. These immunogens generated antibody responses that had increased magnitude and binding breadth compared to soluble gp120. By varying gp120 density on nanofibers, we determined that increased antigen valency was associated with increased antibody magnitude and germinal center responses. This study presents a proof-of-concept for a nanofiber vaccine platform generating broad, high binding antibody responses against the HIV-1 envelope glycoprotein.Chelsea N. FriesJui-Lin ChenMaria L. DennisNicole L. VotawJoshua EudaileyBrian E. WattsKelly M. HainlineDerek W. CainRichard BarfieldCliburn ChanM. Anthony MoodyBarton F. HaynesKevin O. SaundersSallie R. PermarGenevieve G. FoudaJoel H. CollierNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chelsea N. Fries Jui-Lin Chen Maria L. Dennis Nicole L. Votaw Joshua Eudailey Brian E. Watts Kelly M. Hainline Derek W. Cain Richard Barfield Cliburn Chan M. Anthony Moody Barton F. Haynes Kevin O. Saunders Sallie R. Permar Genevieve G. Fouda Joel H. Collier HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth
description	Abstract A major challenge in developing an effective vaccine against HIV-1 is the genetic diversity of its viral envelope. Because of the broad range of sequences exhibited by HIV-1 strains, protective antibodies must be able to bind and neutralize a widely mutated viral envelope protein. No vaccine has yet been designed which induces broadly neutralizing or protective immune responses against HIV in humans. Nanomaterial-based vaccines have shown the ability to generate antibody and cellular immune responses of increased breadth and neutralization potency. Thus, we have developed supramolecular nanofiber-based immunogens bearing the HIV gp120 envelope glycoprotein. These immunogens generated antibody responses that had increased magnitude and binding breadth compared to soluble gp120. By varying gp120 density on nanofibers, we determined that increased antigen valency was associated with increased antibody magnitude and germinal center responses. This study presents a proof-of-concept for a nanofiber vaccine platform generating broad, high binding antibody responses against the HIV-1 envelope glycoprotein.
format	article
author	Chelsea N. Fries Jui-Lin Chen Maria L. Dennis Nicole L. Votaw Joshua Eudailey Brian E. Watts Kelly M. Hainline Derek W. Cain Richard Barfield Cliburn Chan M. Anthony Moody Barton F. Haynes Kevin O. Saunders Sallie R. Permar Genevieve G. Fouda Joel H. Collier
author_facet	Chelsea N. Fries Jui-Lin Chen Maria L. Dennis Nicole L. Votaw Joshua Eudailey Brian E. Watts Kelly M. Hainline Derek W. Cain Richard Barfield Cliburn Chan M. Anthony Moody Barton F. Haynes Kevin O. Saunders Sallie R. Permar Genevieve G. Fouda Joel H. Collier
author_sort	Chelsea N. Fries
title	HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth
title_short	HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth
title_full	HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth
title_fullStr	HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth
title_full_unstemmed	HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth
title_sort	hiv envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9b1d282b3398438e8effddf57c228cf2
work_keys_str_mv	AT chelseanfries hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT juilinchen hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT marialdennis hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT nicolelvotaw hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT joshuaeudailey hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT brianewatts hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT kellymhainline hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT derekwcain hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT richardbarfield hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT cliburnchan hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT manthonymoody hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT bartonfhaynes hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT kevinosaunders hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT sallierpermar hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT genevievegfouda hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth AT joelhcollier hivenvelopeantigenvalencyonpeptidenanofibersmodulatesantibodymagnitudeandbindingbreadth
_version_	1718377995487412224

HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth

Ejemplares similares